Meridian earns CLIA moderate complexity rating for Strep tests

03/20/2013 | GenomeWeb Daily News (free registration)

The FDA has granted moderate complexity status for Meridian Bioscience's Group A and Group B Streptococcus tests under the agency's Clinical Laboratory Improvement Amendments program. The assays, which already have been cleared by the FDA and run on the company's illumigene platform, originally were classified as high complexity tests.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC